US · XOMA
XOMA Royalty Corp.
- Sector
- Healthcare · Biotechnology
- Headquarters
- EmeryVille, CA 94608
- Website
- xoma.com
Price · as of 2024-12-31
$41.38
Market cap 316.14M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $65.60 | +58.53% |
| Intrinsic Value(DCF) | $15.51 | -62.52% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $97.20 | $22,456.18 | $0.00 | $0.00 | $4,049.24 |
| 2011 | $37.20 | $211.04 | $0.00 | $0.00 | $0.00 |
| 2012 | $60.20 | $24.08 | $0.00 | $0.00 | $704.96 |
| 2013 | $126.60 | $50.64 | $0.00 | $0.00 | $0.00 |
| 2014 | $73.80 | $41.35 | $0.00 | $0.00 | $261.20 |
| 2015 | $18.00 | $105.07 | $8.57 | $0.00 | $0.00 |
| 2016 | $6.05 | $3.89 | $0.00 | $0.00 | $693.08 |
| 2017 | $23.19 | $296.04 | $13,992.21 | $10.34 | $1,567.66 |
| 2018 | $14.83 | $859.41 | $0.13 | $0.00 | $124.23 |
| 2019 | $23.17 | $170.82 | $20,892.17 | $3.89 | $0.00 |
| 2020 | $40.91 | $4,393.37 | $8,720.61 | $14.33 | $81.63 |
| 2021 | $24.61 | $69.75 | $8,008.86 | $14.92 | $51.27 |
| 2022 | $21.65 | $187.06 | $8.16 | $0.00 | $108.52 |
| 2023 | $24.71 | $13.07 | $3.15 | $0.00 | $42.56 |
| 2024 | $21.82 | $65.60 | $30.19 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates XOMA Royalty Corp.'s (XOMA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $65.60
- Current price
- $41.38
- AI upside
- +58.53%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$15.51
-62.52% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| XOMA | XOMA Royalty Corp. | $41.38 | 316.14M | +59% | -63% | — | — | -18.47 | 3.12 | 8.96 | -49.66 | — | 4.56 | 99.28% | -140.33% | -48.52% | -16.20% | -36.44% | -6.07% | 1.46 | -2.89 | 5.15 | 5.01 | -3.24 | -5916.00% | 49872.00% | -2425.00% | -5.39% | -0.56 | -17.69% | 2.14% | -39.60% | 2.15% | -6.74 | -19.56 | 9.45 | -6.65 |
| AURA | Aura Biosciences, Inc. | $5.89 | 374.03M | — | — | — | — | -4.23 | 2.42 | — | -2.48 | — | 2.42 | 0.00% | — | — | -46.01% | -494.17% | -39.73% | 0.12 | — | 10.77 | 10.13 | 0.14 | -933.00% | — | 2556.00% | -22.06% | -5.35 | -416.75% | 0.00% | 0.00% | 0.00% | -2.45 | -2.90 | — | 3.57 |
| AUTL | Autolus Therapeutics plc | $1.71 | 455.11M | +3,826% | -33% | — | — | -2.32 | 1.20 | 50.68 | 0.10 | — | 1.24 | -1293.48% | -2385.63% | -2180.45% | -81.91% | 263.57% | -38.11% | 0.12 | -25.98 | 10.88 | 10.47 | 0.75 | -2750.00% | 49600.00% | 5398.00% | -47.01% | -3.40 | 263.21% | 0.00% | 0.00% | 0.00% | 0.09 | 0.09 | -2.23 | -1.19 |
| BNTC | Benitec Biopharma Inc. | $10.90 | 286.09M | — | — | — | — | -13.28 | 5.18 | — | -9.76 | — | 5.18 | 0.00% | — | — | -52.46% | 2846.97% | -49.96% | 0.01 | — | 54.67 | 54.26 | 2.32 | -6082.00% | — | 2055.00% | -4.69% | -13.09 | 1609.13% | 0.00% | 0.00% | 9.20% | -9.74 | -17.23 | — | 128.14 |
| DMAC | DiaMedica Therapeutics In… | $7.95 | 414.02M | — | — | — | — | -9.54 | 5.73 | — | -7.11 | — | 5.73 | 0.00% | — | — | -53.27% | 1178.75% | -48.64% | 0.01 | — | 8.28 | 8.23 | 0.10 | 0.00% | — | 1786.00% | -9.48% | -4.10 | 976.41% | 0.00% | 0.00% | 0.00% | -7.10 | -8.57 | — | 19.75 |
| DSGN | Design Therapeutics, Inc. | $10.44 | 594.7M | — | — | — | — | -5.61 | 1.15 | — | -0.72 | — | 1.15 | 0.00% | — | — | -19.08% | 5921.50% | -18.31% | 0.01 | — | 29.31 | 29.16 | 0.41 | -2605.00% | — | -2613.00% | -15.60% | -5.09 | 4123.87% | 0.00% | 0.00% | 0.75% | -0.57 | -0.81 | — | 15.77 |
| GALT | Galectin Therapeutics Inc… | $2.98 | 192.13M | — | — | — | — | -2.15 | -0.98 | — | -4.63 | -79.38 | -0.98 | 0.00% | — | — | 57.62% | 325.92% | -205.92% | -1.03 | -7.66 | 0.49 | 0.43 | -2.20 | 270.00% | — | 2670.00% | -41.38% | -1.18 | 320.80% | 0.09% | -0.20% | 0.09% | -4.53 | -4.60 | — | -40.88 |
| QSI | Quantum-Si incorporated | $0.96 | 187.03M | +4,402% | -8% | — | — | -1.83 | 0.86 | 60.41 | 0.11 | -41.45 | 0.86 | 52.32% | -3550.56% | -3303.04% | -41.48% | -452.86% | -36.99% | 0.06 | — | 11.99 | 11.60 | 0.35 | 441.00% | 18262.00% | -698.00% | -50.01% | -4.83 | -385.30% | 0.00% | 0.00% | 0.00% | 0.11 | 0.13 | -3.90 | -0.42 |
| RCKT | Rocket Pharmaceuticals, I… | $5.01 | 542.19M | — | — | — | — | -2.48 | 1.99 | — | -2.38 | — | 2.59 | 0.00% | — | — | -60.27% | -135.95% | -52.00% | 0.09 | -122.55 | 6.38 | 2.57 | 0.25 | -2637.00% | — | -1166.00% | -34.48% | -6.29 | -111.72% | 0.00% | 0.00% | 0.00% | -2.16 | -2.62 | — | -1.60 |
| SLDB | Solid Biosciences Inc. | $6.21 | 483.82M | — | — | — | — | -1.77 | 1.61 | — | -0.79 | — | 1.61 | 0.00% | — | — | -94.57% | -623.56% | -70.53% | 0.18 | -381.55 | 5.20 | 4.92 | 0.46 | -3665.00% | — | 519.00% | -45.50% | -3.31 | -483.87% | 0.00% | 0.00% | 6.07% | -0.74 | -0.96 | — | -4.69 |
About XOMA Royalty Corp.
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
- CEO
- Owen Hughes Jr.
- Employees
- 13
- Beta
- 0.86
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($15.51 ÷ $41.38) − 1 = -62.52% (DCF, example).